TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

PHATHOM PHARMACEUTICALS INC

CardiovascularInfectious Disease
Pharma

PHATHOM PHARMACEUTICALS INC is a pharmaceutical company focused on Cardiovascular, Infectious Disease. Key products include VOQUEZNA.

2024
Since
1
Drugs
-
Trials
3
Approved (2yr)

Key Drugs

VOQUEZNA
vonoprazan fumarate
H+, K+-ATPase 4 indications · 2023

Recent Activity

VOQUEZNA 2025-11-06
Labeling
VOQUEZNA 2024-07-17
Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval
VOQUEZNA 2024-07-17
Labeling
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Cardiovascular 54%
1 drugs Phase 3: 1 Phase 2: 1 Phase 1: 1
Infectious Disease 46%
1 drugs Phase 3: 1 Phase 1: 1

Pipeline Strength Pro

Loading...

Competitors Pro

Merck big-pharma
Infectious Disease, Cardiovascular
Baxter specialty
Infectious Disease, Cardiovascular
Johnson & Johnson big-pharma
Infectious Disease, Cardiovascular
B BRAUN specialty
Infectious Disease, Cardiovascular
COSETTE other
Cardiovascular, Infectious Disease